We had expected agro’s weak performance and some impairment on the announced divestment of the foot care brand, Dr Scholl (Consumer Health). Nevertheless, Bayer’s Q2 figures fit into our broad picture, but did not meet consensus at the profitability level. Management had been forced by the weak Q2 to wave the flag. It was not a profit warning, but looks to be quite close to one as it sees the given outlook as ‘increasingly ambitious’. One could interpret this any way.<
30 Jul 2019
Crop Science legacy's weak development
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Crop Science legacy's weak development
Bayer AG (BAYN:WBO) | 0 0 0.5% | Mkt Cap: 80,975m
- Published:
30 Jul 2019 -
Author:
Martin Schnee -
Pages:
3
We had expected agro’s weak performance and some impairment on the announced divestment of the foot care brand, Dr Scholl (Consumer Health). Nevertheless, Bayer’s Q2 figures fit into our broad picture, but did not meet consensus at the profitability level. Management had been forced by the weak Q2 to wave the flag. It was not a profit warning, but looks to be quite close to one as it sees the given outlook as ‘increasingly ambitious’. One could interpret this any way.<